AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25266981 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 100
Study 23733326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic Constant External Resistance (DCER) training
Number of subjects: 31
Study 23733326 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic (ISOK) training
Number of subjects: 31
Study 23733326 — intervention group
Group type: COMPARATOR
Intervention: Control (CONT) group
Number of subjects: 31
Study 20077006 — intervention group
Group type: EXPERIMENTAL
Intervention: Assertive community treatment (ACT) with illness management and recovery (IMR)
Number of subjects: 183
Study 20077006 — intervention group
Group type: COMPARATOR
Intervention: Assertive community treatment (ACT) without IMR
Number of subjects: 183
Study 19202956 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting β-agonists (LABAs) with inhaled corticosteroid (ICS)
Number of subjects: 0
Study 19202956 — intervention group
Group type: COMPARATOR
Intervention: Long-acting β-agonists (LABAs) without inhaled corticosteroid (ICS)
Number of subjects: 0
Study 16122670 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic root-end preparation
Number of subjects: 50
Study 12672582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (75 mg/kg per day, max 2 g/day, intravenously, in two doses until defervescence and continued 5 days after)
Number of subjects: 72
Study 12672582 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol (75 mg/kg per day, max 2 g/day, in four doses for 14 days)
Number of subjects: 72
Study 12672582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 72
Study 12672582 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 72
Study 12672582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone and Chloramphenicol
Number of subjects: 72
Study 10230328 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2.5 mg/kg
Number of subjects: 165
Study 10230328 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 0.3 mg/kg
Number of subjects: 165
Study 10230328 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 5 mg/kg
Number of subjects: 165
Study 8721349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sho‐Seiryu‐To extract
Number of subjects: 0
Study 8721349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sho‐Saiko‐To extract
Number of subjects: 0
Study 8721349 — intervention group
Group type: EXPERIMENTAL
Intervention: Licorice extract
Number of subjects: 0
Study 1992843 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally administered nicotine
Number of subjects: 13
Study 1992843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 6839667 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 30
Study 6839667 — intervention group
Group type: COMPARATOR
Intervention: Low-protein formula (casein)
Number of subjects: 30
Study 6839667 — intervention group
Group type: COMPARATOR
Intervention: Low-protein formula (whey)
Number of subjects: 30
Study 31916033 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement with immediate provisionalization (TG)
Number of subjects: 12
Study 31916033 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with immediate implants with intact alveoli
Number of subjects: 12
Study 30945798 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-coil leads (SC-leads)
Number of subjects: 2475
Study 30945798 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-coil leads (DC-leads)
Number of subjects: 2475
Study 28388294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizzy Diet + FitMiss Burn (BURN)
Number of subjects: 39
Study 28388294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bizzy Diet + Placebo (PLA)
Number of subjects: 39
Study 28388294 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 39
Study 26808384 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Depth of Focus lenses (EDOF)
Number of subjects: 41
Study 24552382 — intervention group
Group type: EXPERIMENTAL
Intervention: JUICE (freeze-dried fruit and vegetable juice powder)
Number of subjects: 34
Study 24552382 — intervention group
Group type: COMPARATOR
Intervention: Control (nonJUICE)
Number of subjects: 34
Study 22623016 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (350 mg)
Number of subjects: 10
Study 22623016 — intervention group
Group type: COMPARATOR
Intervention: Hydromorphone (16 mg)
Number of subjects: 10
Study 22623016 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg)
Number of subjects: 10
Study 22623016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19509107 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human TSH injections (0.9 mg im per 2 consecutive days) - group B
Number of subjects: 20
Study 19509107 — intervention group
Group type: COMPARATOR
Intervention: Levothyroxine withdrawal (30 days) - group A
Number of subjects: 20
Study 16870661 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTM1 null genotype
Number of subjects: 151
Study 16870661 — intervention group
Group type: EXPERIMENTAL
Intervention: GSTP1 Valine/Valine genotype
Number of subjects: 151
Study 16870661 — intervention group
Group type: EXPERIMENTAL
Intervention: Both GSTM1 null and GSTP1 Val/Val genotypes
Number of subjects: 151
Study 16870661 — intervention group
Group type: COMPARATOR
Intervention: GSTP1 genotypes
Number of subjects: 151
Study 15747762 — intervention group
Group type: EXPERIMENTAL
Intervention: Early retinal ablative treatment
Number of subjects: 317
Study 15747762 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (control eye)
Number of subjects: 317
Study 11709366 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir with saquinavir soft gel capsule
Number of subjects: 31
Study 11709366 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir with indinavir
Number of subjects: 31
Study 11709366 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir with nelfinavir
Number of subjects: 31
Study 11709366 — intervention group
Group type: COMPARATOR
Intervention: Nelfinavir and saquinavir with amprenavir
Number of subjects: 31
Study 11709366 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with amprenavir
Number of subjects: 31
Study 9046304 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg per day tirilazad
Number of subjects: 897
Study 9046304 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg per day tirilazad
Number of subjects: 897
Study 9046304 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 897
Study 9046304 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including placebo and both doses of tirilazad)
Number of subjects: 897
Study 7931028 — intervention group
Group type: EXPERIMENTAL
Intervention: 15‐mg diphenhydramine hydrochloride (Benadryl) local injection
Number of subjects: 37
Study 7931028 — intervention group
Group type: COMPARATOR
Intervention: Sterile saline (control group)
Number of subjects: 37
Study 3336177 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alfa (Alferon N Injection), injected into lesions twice weekly for up to eight weeks.
Number of subjects: 158
Study 3336177 — intervention group
Group type: COMPARATOR
Intervention: Placebo, injected into lesions twice weekly for up to eight weeks.
Number of subjects: 158
Study 30342242 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-specific specialty palliative care consultation plus postacute transitional care
Number of subjects: 62
Study 30342242 — intervention group
Group type: COMPARATOR
Intervention: Usual care and educational information
Number of subjects: 62
Study 28302543 — intervention group
Group type: EXPERIMENTAL
Intervention: Pidotimod (PDT) 800mg, 2 daily doses
Number of subjects: 16
Study 28302543 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg b.i.d. alone
Number of subjects: 16
Study 26894598 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 120
Study 23343392 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated pharmacological bone health and falls prevention program post-fracture
Number of subjects: 1596
Study 23343392 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1596
Study 21701222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days
Number of subjects: 60
Study 21701222 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 21701222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethylsuccinate
Number of subjects: 60
Study 19051397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tenofovir HIV prevention trial
Number of subjects: 0
Study 19051397 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV prevention counseling associated with the trial
Number of subjects: 0
Study 15080578 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg every 12 hours for 7 days)
Number of subjects: 81
Study 15080578 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg every 12 hours for 7 days)
Number of subjects: 81
Study 15080578 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 81
Study 12243437 — intervention group
Group type: EXPERIMENTAL
Intervention: Carmeda Bio‐Active Surface (CBAS)
Number of subjects: 40
Study 12243437 — intervention group
Group type: COMPARATOR
Intervention: Duraflo II coating
Number of subjects: 40
Study 12243437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBAS and Duraflo II)
Number of subjects: 40
Study 9824784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m2 by infusion over 2 hours
Number of subjects: 26
Study 9824784 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 80 mg/m2 by infusion over 3.5 hours
Number of subjects: 26
Study 9824784 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 80 mg/m2 by infusion over 4 hours
Number of subjects: 26
Study 9824784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) pharmacodynamics
Number of subjects: 26
Study 9824784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) pharmacokinetics
Number of subjects: 26
Study 9824784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) nephrotoxicity management
Number of subjects: 26
Study 8109552 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine (100 micrograms/day)
Number of subjects: 20
Study 8109552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2697690 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine fortified oral rehydration solution (ORS)
Number of subjects: 0
Study 2697690 — intervention group
Group type: COMPARATOR
Intervention: Standard ORS (WHO formula)
Number of subjects: 0
Study 1256990 — intervention group
Group type: EXPERIMENTAL
Intervention: Work intensity at 60% of HRmax
Number of subjects: 0
Study 1256990 — intervention group
Group type: EXPERIMENTAL
Intervention: Work intensity at 75% of HRmax
Number of subjects: 0
Study 1256990 — intervention group
Group type: EXPERIMENTAL
Intervention: Work intensity at 90% of HRmax
Number of subjects: 0
Study 1256990 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 31286425 — intervention group
Group type: EXPERIMENTAL
Intervention: PHIV+
Number of subjects: 39
Study 27510440 — intervention group
Group type: EXPERIMENTAL
Intervention: Irremovable instant total contact cast (iTCC)
Number of subjects: 49
Study 27510440 — intervention group
Group type: COMPARATOR
Intervention: Removable cast walker (RCW)
Number of subjects: 49
Study 27510440 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 27510440 — intervention group
Group type: EXPERIMENTAL
Intervention: RCW patients
Number of subjects: 49
Study 27510440 — intervention group
Group type: EXPERIMENTAL
Intervention: Standing duration
Number of subjects: 49
Study 25813474 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational oncology interventions
Number of subjects: 0
Study 23140612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (17 mg/kg cumulative dose)
Number of subjects: 64
Study 23140612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 64
Study 23140612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 64
Study 23140612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 21569094 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.2% CHX)
Number of subjects: 50
Study 21569094 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 50
Study 19633166 — intervention group
Group type: EXPERIMENTAL
Intervention: eAG
Number of subjects: 80
Study 19633166 — intervention group
Group type: COMPARATOR
Intervention: A1C
Number of subjects: 80
Study 16394754 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic extensor brace treatment for 12 weeks (Group 1; n = 30)
Number of subjects: 63
Study 16394754 — intervention group
Group type: COMPARATOR
Intervention: No brace treatment (Group 2; n = 33)
Number of subjects: 63
Study 15175795 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet intervention (Mediterranean type diet)
Number of subjects: 219
Study 15175795 — intervention group
Group type: EXPERIMENTAL
Intervention: VLC n‐3 supplementation
Number of subjects: 219
Study 15175795 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice (Mediterranean type diet)
Number of subjects: 219
Study 15175795 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 219
Study 11521726 — intervention group
Group type: EXPERIMENTAL
Intervention: AC → paclitaxel + trastuzumab
Number of subjects: 0
Study 11521726 — intervention group
Group type: COMPARATOR
Intervention: AC → paclitaxel
Number of subjects: 0
Study 11521726 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study 11521726 — intervention group
Group type: EXPERIMENTAL
Intervention: AC → paclitaxel + tamoxifen
Number of subjects: 0
Study 9230637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NTP) 70 mg initially, increased to 75 mg based on serum levels
Number of subjects: 16
Study 9230637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nortriptyline (NTP) treatment
Number of subjects: 16
Study 8231841 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) for 6 weeks
Number of subjects: 9
Study 8231841 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) for 26 weeks
Number of subjects: 9
Study 8231841 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 9
Study 8231841 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks
Number of subjects: 9
Study 3631260 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.1 microgram/min
Number of subjects: 5
Study 3631260 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 5
Study 30882163 — intervention group
Group type: EXPERIMENTAL
Intervention: Irrigation fluid at 37°C (GroupW)
Number of subjects: 60
Study 30882163 — intervention group
Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature (GroupRT)
Number of subjects: 60
Study 28926170 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus metformin
Number of subjects: 630
Study 28926170 — intervention group
Group type: COMPARATOR
Intervention: Saxagliptin 5 mg plus placebo
Number of subjects: 630
Study 28926170 — intervention group
Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 630
Study 28926170 — intervention group
Group type: EXPERIMENTAL
Intervention: Saxagliptin plus metformin
Number of subjects: 630
Study 27717405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 128
Study 27717405 — intervention group
Group type: COMPARATOR
Intervention: Group Schema Therapy (GST)
Number of subjects: 128
Study 24894696 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIR 40 protocol (Group A)
Number of subjects: 53
Study 24894696 — intervention group
Group type: COMPARATOR
Intervention: Standard FBP protocol (Group B)
Number of subjects: 53
Study 22232134 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1150
Study 22232134 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1150
Study 22232134 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1150
Study 19707760 — intervention group
Group type: EXPERIMENTAL
Intervention: Open wedge osteotomy (OWO)
Number of subjects: 50
Study 19707760 — intervention group
Group type: COMPARATOR
Intervention: Closed wedge osteotomy (CWO)
Number of subjects: 50
Study 18247099 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotherapy (trans‐ampullary pancreatic stents for drainage)
Number of subjects: 380
Study 18247099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resections
Number of subjects: 380
Study 18247099 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical drainage
Number of subjects: 380
Study 18247099 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotherapy with or without shock wave lithotripsy
Number of subjects: 380
Study 28406090 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 evogliptin/metformin XR 2.5/500 mg FDC tablets
Number of subjects: 33
Study 28406090 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations of evogliptin 5 mg and metformin XR 1,000 mg
Number of subjects: 33
Study 11855559 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal therapy (CSWT) alone
Number of subjects: 42
Study 11855559 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid withdrawal therapy (CSWT) followed by interferon-alpha (IFN-alpha)
Number of subjects: 42
Study 10378970 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive radiotherapy after aggressive surgery and chemotherapy
Number of subjects: 0
Study 10378970 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional irradiation incorporating internal mammary nodes
Number of subjects: 0
Study 10378970 — intervention group
Group type: COMPARATOR
Intervention: Optimal sequencing of radiotherapy and chemotherapy
Number of subjects: 0
Study 7794631 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 5
Study 2260546 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality survey for cardiovascular disease
Number of subjects: 4500
Study 2260546 — intervention group
Group type: EXPERIMENTAL
Intervention: Morbidity survey for myocardial infarction and stroke
Number of subjects: 4500
Study 2260546 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 4500
Study 2260546 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal interviews
Number of subjects: 4500
Study 2260546 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 4500
Study 2260546 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory measurements
Number of subjects: 4500
Study 15295 — intervention group
Group type: EXPERIMENTAL
Intervention: Medazepam (16.5 mg daily)
Number of subjects: 14
Study 31232684 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal temperature-controlled laminar airflow (TLA) device
Number of subjects: 240
Study 31232684 — intervention group
Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 240
Study 28711811 — intervention group
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine (2400 mg/day)
Number of subjects: 14
Study 28711811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 25583758 — intervention group
Group type: EXPERIMENTAL
Intervention: DCR+RCR group (Distal Clavicle Resection + Rotator Cuff Repair)
Number of subjects: 56
Study 25583758 — intervention group
Group type: COMPARATOR
Intervention: Isolated RCR group (Rotator Cuff Repair only)
Number of subjects: 56
Study 25583758 — intervention group
Group type: EXPERIMENTAL
Intervention: DCR+RCR group
Number of subjects: 56
Study 25583758 — intervention group
Group type: COMPARATOR
Intervention: Isolated RCR group
Number of subjects: 56
Study 23815302 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose alemtuzumab (15 mg at day 0 and 15 mg repeated on day 7)
Number of subjects: 0
Study 23815302 — intervention group
Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 0
Study 23815302 — intervention group
Group type: COMPARATOR
Intervention: Conventional 4-dose alemtuzumab
Number of subjects: 0
Study 21658528 — intervention group
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP)
Number of subjects: 49
Study 21658528 — intervention group
Group type: COMPARATOR
Intervention: Community care condition
Number of subjects: 49
Study 19548434 — intervention group
Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao Powder (JXYP)
Number of subjects: 33
Study 19548434 — intervention group
Group type: EXPERIMENTAL
Intervention: Estazolam (WM group)
Number of subjects: 33
Study 19548434 — intervention group
Group type: EXPERIMENTAL
Intervention: JXYP plus Estazolam (IM group)
Number of subjects: 33
Study 19548434 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 33
Study 16940830 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily amoxicillin (750 mg or 1000 mg) for 10 days
Number of subjects: 652
Study 16940830 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily amoxicillin (2 doses of 375 mg or 500 mg) for 10 days
Number of subjects: 652
Study 16940830 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily amoxicillin
Number of subjects: 652
Study 16940830 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily amoxicillin
Number of subjects: 652
Study 15473127 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose sulfonylurea (Glimepiride 8 patients, gliclazide 5 patients)
Number of subjects: 52
Study 15473127 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 2 x 2 mg
Number of subjects: 52
Study 15473127 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic diet only
Number of subjects: 52
Study 15473127 — intervention group
Group type: COMPARATOR
Intervention: Single dose sulfonylurea (Group 2)
Number of subjects: 52
Study 15473127 — intervention group
Group type: COMPARATOR
Intervention: Repaglinide (Group 3)
Number of subjects: 52